{"filing":{"accession_number":"0001193125-26-233507","cik":"0001595097","ticker":"CRBP","company_name":"Corbus Pharmaceuticals Holdings, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"crbp-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/crbp-20260519.htm"},"events":[{"id":9381,"run_id":8226,"accession_number":"0001193125-26-233507","anchor_item_number":"1.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Corbus Pharmaceuticals appointed Nishant Saxena as Chief Business Officer effective May 21, 2026, under a two-year employment agreement with base salary of $470,000 and equity grants of 192,300 stock options and 58,300 RSUs.","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1000,"accession_number":"0001193125-26-233507","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses Corbus Pharmaceuticals' entry into an employment agreement with Nishant Saxena effective May 21, 2026, appointing him as Chief Business Officer with a two-year term. While the Item 1.01 caption references \"Material Definitive Agreement,\" the substance centers on the appointment of a named executive officer with significant compensation (base salary $470,000, equity grants of 192,300 stock options and 58,300 RSUs, and severance provisions). This is material to investors as a C-suite appointment affecting corporate governance and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:36:35.858467+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1002,"accession_number":"0001193125-26-233507","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Mr. Saxena as Chief Business Officer, which is a material executive appointment. While the Item 7.01 disclosure also mentions a conference call regarding clinical data, the principal disclosed action is the appointment of a named executive to a senior officer role. Executive appointments to C-suite positions materially affect investor assessment of company leadership and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:36:35.858467+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":9382,"run_id":8226,"accession_number":"0001193125-26-233507","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Brent Pfeiffenberger received equity compensation awards in connection with his Board appointment: a nonqualified stock option for 24,700 shares and a restricted stock unit award for 7,500 shares, both vesting over three years.","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1001,"accession_number":"0001193125-26-233507","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on equity compensation awards granted to Brent Pfeiffenberger in connection with his Board appointment: a nonqualified stock option for 24,700 shares and a restricted stock unit award for 7,500 shares, both vesting over three years. While the section mentions his appointment, the substantive disclosure focuses on the compensatory arrangements themselves, making this an exec_compensation event rather than exec_appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:36:35.858467+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1000,"accession_number":"0001193125-26-233507","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses Corbus Pharmaceuticals' entry into an employment agreement with Nishant Saxena effective May 21, 2026, appointing him as Chief Business Officer with a two-year term. While the Item 1.01 caption references \"Material Definitive Agreement,\" the substance centers on the appointment of a named executive officer with significant compensation (base salary $470,000, equity grants of 192,300 stock options and 58,300 RSUs, and severance provisions). This is material to investors as a C-suite appointment affecting corporate governance and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:36:35.858467+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-21"},{"id":1001,"accession_number":"0001193125-26-233507","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on equity compensation awards granted to Brent Pfeiffenberger in connection with his Board appointment: a nonqualified stock option for 24,700 shares and a restricted stock unit award for 7,500 shares, both vesting over three years. While the section mentions his appointment, the substantive disclosure focuses on the compensatory arrangements themselves, making this an exec_compensation event rather than exec_appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:36:35.858467+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-21"},{"id":1002,"accession_number":"0001193125-26-233507","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the appointment of Mr. Saxena as Chief Business Officer, which is a material executive appointment. While the Item 7.01 disclosure also mentions a conference call regarding clinical data, the principal disclosed action is the appointment of a named executive to a senior officer role. Executive appointments to C-suite positions materially affect investor assessment of company leadership and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:36:35.858467+00:00","company_name":"Corbus Pharmaceuticals Holdings, Inc.","ticker":"CRBP","filing_date":"2026-05-21"}]}